PLGA nanoparticles have been designed for the transportation of cytokine agonists, siRNAs, or CpG-coated tumor antigens to enhance antigen uptake by DCs and trigger both CTL (CD8+) and Th (CD4+) immune responses [138,139,140]. The gene discussed is CD4; the disease is neoplasm.